Urinary ACE2 is associated with urinary L-FABP and albuminuria in patients with chronic kidney disease

References

• Lewis EJ, Hunsicker LG, Carke WR, Berl T, Pohl MA, Lewis JB, Ritz E, Atkins RC, Rohde R, Raz I. Renoprotective effect of angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001;345:851–60.
   PubMed Web of Science ®Google Scholar
• Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH, Remuzzi G, Snapinn SM, Zhang Z, Shahinfar S. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001;345:861–9.
   PubMed Web of Science ®Google Scholar
• Wolf G, Ziyadeh FN. The role of angiotensin II in diabetic nephropathy: emphasis on nonhemodynamic mechanisms. Am J Kidney Dis 1997;29:153–63.
   PubMed Web of Science ®Google Scholar
• Donoghue M, Hsieh F, Baronas E, Godbout K, Gosselin M, Stagliano N, Donovan M, Woolf B, Robison K, Jeyaseelan R, Breitbart RE, Acton S. A novel angiotensin-converting enzyme-related carboxypeptide (ACE2) converts angiotensin I to angiotensin 1-9. Circ Res 2000;87:1–9.
   PubMed Web of Science ®Google Scholar
• Tipnis SR, Hooper NM, Hyde R, Karran E, Christie G, Turner AJ. A human homolog of angiotensin-converting enzyme. Cloning and functional expression as a captopril-insensitive carboxypeptidase. J Biol Chem 2000;275: 33238–43.
   PubMed Web of Science ®Google Scholar
• Li N, Zimpelmann J, Cheng K, Wilkins JA, Burns KD. The role of angiotensin converting enzyme 2 in the generation of angiotensin 1-7 by rat proximal tubules. Am J Physiol Renal Physiol 2005;288:353–2.
   PubMed Web of Science ®Google Scholar
• Shaltout HA, Westwood BM, Averill DB, Ferrario GM, Figueroa JP, Diz DI, Rose JC, Chappell MC. Angiotensin metabolism in renal proximal tubules, urine, and serum of sheep: evidence for ACE2-dependent processing of angiotensin II. Am J Physiol Renal Physiol 2007;292: F82–91.
   PubMed Web of Science ®Google Scholar
• Ye M, Wysocki J, Naaz P, Salabat MR, LaPointe MS, Batlle D. Increased ACE2 and decreased ACE protein in renal tubules from diabetic mice: a renoprotective combination? Hypertension 2004;43:1120–5.
   PubMed Web of Science ®Google Scholar
• Oudit GY, Herzenberg AM, Kassiri Z, Wong D, Reich H. Loss of angiotensin-converting enzyme-2 leads to the late development of angiotensin II-dependent glomerulosclerosis. Am J Pathol 2006;168:1808–20.
   PubMed Web of Science ®Google Scholar
• Wong DW, Oudit GY, Reich H, Kassiri Z, Zhou J. Loss of angiotensin-converting enzyme-2 (Ace2) accelerates diabetic kidney injury. Am J Pathol 2007;171:438–51.
   PubMed Web of Science ®Google Scholar
• Wysocki J, Ye M, Rodriguez E, Gonzalez-Pacheco FR, Barrios C. Targeting the degradation of angiotensin II-dependent hypertension. Hypertension 2010;55:90–8.
   PubMed Web of Science ®Google Scholar
• Oudit GY, Liu GC, Zhong J, Basu R, Chow FL, Zhou J, Loibner H, Janzek E, Schuster M, Penninger JM, Herzenberg AM, Kassiri Z, Scholey JW. Human recombinant ACE2 reduces the progression of diabetic nephropathy. Diabetes 2010;59:529–38.
   PubMed Web of Science ®Google Scholar
• Gross JL, de Azevedo MJ, Silveiro SP, Canani LH, Caramori ML, Zelmanovitz T. Diabetic nephropathy: diagnosis, prevention, and treatment. Diabetes Care 2005; 28:164–76.
   PubMed Web of Science ®Google Scholar
• Japanese Society of Hypertension. Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2009). Hypertens Res 2009;32:4–107.
   Web of Science ®Google Scholar
• Matsuo S, Imai E, Horio M, Yasuda Y, Tomita K, Nitta K, Yamagata K, Tomino Y, Yokoyama H, Hishida A. Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis 2009;53:982–92.
   PubMed Web of Science ®Google Scholar
• Xiao F, Hiremath S, Knoll G, Zimpelmann J, Srivaratharajar K, Jadhav D, Ferqusson D, Kennedy CR, Burns KD. Increased urinary angiotensin-converting enzyme 2 in renal transplant patients with diabetes. PLos One 2012;7:e37649.
   Google Scholar
• Mizuiri S, Aoki T, Hemmi H, Arita M, Sakai K, Aikawa A. Urinary ACE2 in patients with CKD. Nephrology 2011;16:567–72.
   PubMed Web of Science ®Google Scholar
• Schalekamp MA, Danser AH. Angiotensin II production and distribution in the kidney: I. A kinetic model. Kidney Int 2006;69:1543–52.
   PubMed Web of Science ®Google Scholar
• Santos RA, Simoes e Silva AC, Maric C, Silva DM, Machado RP, de Buhr I, Heringer-Walther S, Pinheiro SV, Lopes MT, Bader M, Mendes EP, Lemos VS, Campaqnole–Santos MJ, Schultheiss HP, Speth R, Walther T. Angiotensin-(1-7) is an endogenous ligand for the G protein-coupled receptor Mas. Proc Natl Acad Sci USA 2003;100:8258–63.
   PubMed Web of Science ®Google Scholar
• Ferrario CM, Varagic J. The ANG-(1-7)/ACE2/mas axis in the regulation of nephron function. Am J Physiol Renal Physiol 2010;298:F1297–305.
   PubMed Web of Science ®Google Scholar
• Iwai M, Nakaoka H, Senba I, Kanno H, Moritani T, Horiuchi M. Possible involvement of angiotensin- converting enzyme 2 and mas activation in inhibitory effects of angiotensin II type 1 receptor blockade on vascular remodeling. Hypertension 2012;60:137–44.
   PubMed Web of Science ®Google Scholar
• Grobe JL, Mecca AP, Lingis M, Shenov V, Bolton TA, Machado JM, Speth RC, Raizada MK, Katovich MJ. Prevention of angiotensin II-induced cardiac remodeling by angiotensin-(1-7). Am J Physiol Heart Circ Physiol 2007;292:H736–42.
   PubMed Web of Science ®Google Scholar
• Zhong J, Basu R, Guo D, Chow FL, Byrns S, Schuster M, Loibner H, Wang XH, Penninger JM, Kassiri Z, Oudit GY. Angiotensin-converting enzyme 2 suppresses pathological hypertrophy, myocardial fibrosis, and cardiac dysfunction. Circulation 2010;122:717–28.
   PubMed Web of Science ®Google Scholar
• Alenina N, Xu P, Rentzsch B, Patkin EL, Bader M. Genetically altered animal models for Mas and angiotensin-(1-7). Exp Physiol 2008;93:528–37.
   PubMed Web of Science ®Google Scholar
• Burgelova M, Kramer HJ, Teplan V, Thumova M, Cervenka L. Effects of angiotensin (1-7) blockade on renal function in rats with enhanced intrarenal Ang II activity. Kidney Int 2005;67:1453–61.
   PubMed Web of Science ®Google Scholar
• Burgelova M, Kramer HJ, Teplan V, Velickova G, Vitko S, Heller J, Maly J, Cervenka L. Intrarenal infusion of angiotensin-(1-7) modulates renal functional responses to exogenous angiotensin II in the rat. Kidney Blood Press Res 2002;25:202–10.
   PubMed Web of Science ®Google Scholar
• Shiota A, Yamamoto K, Ohishi M, Tatara Y, Ohnishi M, Maekawa Y, Iwamoto Y, Takeda M, Rakugi H. Loss of ACE2 accelerates time-dependent glomerular and tubulointerstitial damage in streptozotocin-induced diabetic mice. Hypertens Res 2010;33:298–307.
   PubMed Web of Science ®Google Scholar
• Thomas MC, Burns WC, Cooper ME. Tubular changes in early diabetic nephropathy. Adv Chronic Kid Dis 2005;12: 177–86.
   PubMed Web of Science ®Google Scholar
• Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature 2001;414:818–20.
   Web of Science ®Google Scholar
• Goodarzi MT, Navidi AA, Rezaei M, Rezaei HB. Oxidative damage to DNA and lipids: correlation with protein glycation in patients with type 1 diabetes. J Clin Lab Anal 2010;24:71–6.
   Web of Science ®Google Scholar
• Kamijo A, Kimura K, Sugaya T, Yamanouchi M, Hikawa A, Hirano N, Hirata Y, Goto A, Omata M. Urinary fatty acid-binding protein as a new clinical marker of the progression of chronic renal disease. J Lab Clin Med 2004; 143: 23–30.
   PubMed Web of Science ®Google Scholar
• Sheetz MJ, King GL. Molecular understanding of hyperglycemia's adverse effects for diabetic complications. JAMA 2002; 288: 2579–88.
   PubMed Web of Science ®Google Scholar
• Nakamura T, Sugaya T, Kawagoe Y, Ueda Y, Osada S, Koide H. Effect of pitavastatin on urinary liver-type fatty acid-binding protein levels in patients with early diabetic nephropathy. Diabetes Care 2005;28:2728–32.
   PubMed Web of Science ®Google Scholar
• Abe M, Matuyama N, Okada K, Matsumoto S, Matsumoto K, Soma M. Effects of lipid-lowering therapy with rosuvastatin on kidney function and oxidative stress in patients with diabetic nephropathy. J Atheroscler Thromb 2011;18:1018–28.
   PubMed Web of Science ®Google Scholar
• Abe M, Oikawa O, Okada K, Soma M. Urinary angiotensin-converting enzyme 2 increases in diabetic nephropathy by angiotensin II type 1 receptor blocker olmesartan. J Renin Angiotensin Aldosterone Syst 2015;16:159–164.
   PubMed Web of Science ®Google Scholar
• Ye M, Wvsocki J, William J, Soler MJ, Cokic I, Batlle D. Glomerular localization and expression of angiotensin-converting enzyme 2 and angiotensin-converting enzyme: implications for albuminuria in diabetes. J Am Soc Nephrol 2006;17:3067–75.
   PubMed Web of Science ®Google Scholar
• Agata J, Ura N, Yoshida H, Shinshi Y, Sasaki H, Hyakkoku M Taniguchi S, Shimamoto K. Olmesartan is angiotensin II receptor blocker with an inhibitory effect on angiotensin-converting enzyme. Hypertens Res 2006;29:865–74.
   PubMed Web of Science ®Google Scholar